A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

[1]  R. Dellavalle,et al.  The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study , 2021, Frontiers in Medicine.

[2]  B. Strober,et al.  Bimekizumab versus Secukinumab in Plaque Psoriasis. , 2021, The New England journal of medicine.

[3]  Y. Lee,et al.  Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis. , 2021, International journal of clinical pharmacology and therapeutics.

[4]  D. Baeten,et al.  IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong? , 2021, Frontiers in Immunology.

[5]  K. Reich,et al.  Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial , 2021, The Lancet.

[6]  K. Kridin,et al.  47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) , 2021, Experimental dermatology.

[7]  B. Elewski,et al.  Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review , 2020, American Journal of Clinical Dermatology.

[8]  Michael P. Lee,et al.  Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. , 2020, Cutis.

[9]  A. Lawson,et al.  Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F , 2020, Frontiers in Immunology.

[10]  A. Armstrong,et al.  Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. , 2020, JAMA.

[11]  Irah L. King,et al.  Innate Lymphocytes in Psoriasis , 2020, Frontiers in Immunology.

[12]  M. Jaeger,et al.  Recurrent Vulvovaginal Candidiasis: An Immunological Perspective , 2020, Microorganisms.

[13]  A. Sultan,et al.  Oral Candidiasis: A Disease of Opportunity , 2020, Journal of fungi.

[14]  S. Gaffen,et al.  Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity , 2020, Science Immunology.

[15]  U. Mrowietz,et al.  Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment , 2019, The Journal of experimental medicine.

[16]  A. Mohamed,et al.  Diagnosis and Treatment of Esophageal Candidiasis: Current Updates , 2019, Canadian journal of gastroenterology & hepatology.

[17]  M. Komine,et al.  Risk Factors for the Development of Psoriasis , 2019, International journal of molecular sciences.

[18]  T. Beikler,et al.  Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases , 2019, International journal of molecular sciences.

[19]  C. Marek,et al.  Candidiasis: Red and White Manifestations in the Oral Cavity , 2019, Head and Neck Pathology.

[20]  M. Umeda,et al.  A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer , 2018, Medicine.

[21]  D. Katzka,et al.  Infections of the esophagus: an update on risk factors, diagnosis, and management. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[22]  A. Blauvelt,et al.  The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis , 2018, Clinical Reviews in Allergy & Immunology.

[23]  J. Roliński,et al.  Prevalence and Possible Role of Candida Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis , 2018, Mediators of inflammation.

[24]  S. Tavakolpour,et al.  Oral Candida colonization and plaque type psoriasis: Is there any relationship? , 2018, Journal of investigative and clinical dentistry.

[25]  M. Umemura,et al.  Interleukin‐17 family cytokines in protective immunity against infections: role of hematopoietic cell‐derived and non‐hematopoietic cell‐derived interleukin‐17s , 2018, Microbiology and immunology.

[26]  B. Peters,et al.  Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: “Neutrophil Anergy” , 2017, Infection and Immunity.

[27]  D. Williams,et al.  Diagnosis and management of oral candidosis , 2017, BDJ.

[28]  S. Gaffen,et al.  Innate Immunity to Mucosal Candida Infections , 2017, Journal of fungi.

[29]  C. Zachariae,et al.  Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management , 2017, The British journal of dermatology.

[30]  J. Kolls,et al.  Interluekin-17A (IL17A). , 2017, Gene.

[31]  M. Veldhoen.  Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.

[32]  L. Taams,et al.  IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory disease , 2016, Immunology letters.

[33]  M. Nguyen,et al.  Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework , 2016, Infection and Immunity.

[34]  G. Adams,et al.  Oral candidal carriage in asymptomatic patients. , 2016, Australian dental journal.

[35]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  L. Joosten,et al.  Immune defence against Candida fungal infections , 2015, Nature Reviews Immunology.

[37]  A. Mantovani,et al.  Interleukin-17 and innate immunity in infections and chronic inflammation. , 2015, Journal of autoimmunity.

[38]  B. Soltész,et al.  The Evolving View of IL-17-Mediated Immunity in Defense Against Mucocutaneous Candidiasis in Humans , 2015, International reviews of immunology.

[39]  M. Lebwohl,et al.  IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies , 2015, The Journal of investigative dermatology.

[40]  J. Bagan,et al.  Current treatment of oral candidiasis: A literature review , 2014, Journal of clinical and experimental dentistry.

[41]  A. Puel,et al.  IL-17 and infections. , 2014, Actas dermo-sifiliograficas.

[42]  L. Skov,et al.  Targeting of interleukin-17 in the treatment of psoriasis , 2014, Clinical, cosmetic and investigational dermatology.

[43]  Y. Jiménez-Soriano,et al.  Clinical and microbiological diagnosis of oral candidiasis , 2013, Journal of clinical and experimental dentistry.

[44]  L. Patton,et al.  Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. , 2013, Journal of the California Dental Association.

[45]  J. Casanova,et al.  Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis , 2012, Current opinion in allergy and clinical immunology.

[46]  H. Kang,et al.  Prevalence and Risk Factors of Esophageal Candidiasis in Healthy Individuals: A Single Center Experience in Korea , 2012, Yonsei medical journal.

[47]  M. Al-Aboosi,et al.  Oral Candida colonization and candidiasis in patients with psoriasis. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.

[48]  P. Krishnan,et al.  Fungal infections of the oral mucosa. , 2012, Indian journal of dental research : official publication of Indian Society for Dental Research.

[49]  C. Bodemer,et al.  Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity , 2011, Science.

[50]  Yoichiro Iwakura,et al.  Review Functional Specialization of Interleukin-17 Family Members , 2022 .

[51]  K. Shetty,et al.  Diagnosis and management of oral candidiasis. , 2011, Otolaryngologic clinics of North America.

[52]  T. Young,et al.  Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2010, The Cochrane database of systematic reviews.

[53]  C. Farah,et al.  Oral fungal infections: an update for the general practitioner. , 2010, Australian dental journal.

[54]  A. Parolia,et al.  Asthma and oral health: a review. , 2010, Australian dental journal.

[55]  S. Gaffen,et al.  Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease , 2010, Immunology.

[56]  S. Way,et al.  Interleukin‐17 in host defence against bacterial, mycobacterial and fungal pathogens , 2009, Immunology.

[57]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[58]  C. Fichtenbaum,et al.  A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  G. Slade,et al.  Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.

[60]  J. Chave,et al.  Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. , 2002, The Journal of antimicrobial chemotherapy.

[61]  J. Malo,et al.  Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. , 2000, Journal of clinical epidemiology.

[62]  S. Hilsenbeck,et al.  A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. , 1998, The American journal of medicine.

[63]  W. El-Sadr,et al.  Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection , 1997, Annals of Internal Medicine.

[64]  D. Marriott,et al.  Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study , 1993, The Medical journal of Australia.

[65]  D. Stevens,et al.  Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. , 1991, Archives of internal medicine.

[66]  E. Dunbar,et al.  Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. , 1990, The Journal of infection.

[67]  P. Rompré,et al.  Reassessing the presence of Candida albicans in denture-related stomatitis. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.